Guardant Health, Inc. $GH Shares Bought by Future Fund LLC

Future Fund LLC grew its holdings in Guardant Health, Inc. (NASDAQ:GH) by 26.2% in the first quarter, Holdings Channel.com reports. The institutional investor owned 46,465 shares of the company’s stock after acquiring an additional 9,638 shares during the quarter. Guardant Health comprises 1.5% of Future Fund LLC’s investment portfolio, making the stock its 11th largest holding. Future Fund LLC’s holdings in Guardant Health were worth $4,292,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. AQR Capital Management LLC increased its holdings in shares of Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after purchasing an additional 25,831 shares during the period. Empowered Funds LLC purchased a new position in Guardant Health in the 1st quarter valued at $274,000. Sei Investments Co. increased its stake in Guardant Health by 15.8% in the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after buying an additional 10,538 shares during the period. The Manufacturers Life Insurance Company raised its position in Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock worth $32,922,000 after buying an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock worth $5,800,000 after buying an additional 40,209 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Insider Activity at Guardant Health

In other Guardant Health news, insider John G. Saia sold 20,000 shares of the stock in a transaction dated Wednesday, May 20th. The shares were sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider directly owned 45,950 shares of the company’s stock, valued at approximately $4,894,134.50. This trade represents a 30.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Meghan V. Joyce sold 10,000 shares of Guardant Health stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $126.98, for a total transaction of $1,269,800.00. Following the sale, the director owned 11,183 shares of the company’s stock, valued at approximately $1,420,017.34. The trade was a 47.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 708,565 shares of company stock valued at $90,556,597 in the last ninety days. Company insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on GH. Evercore reaffirmed an “outperform” rating and issued a $200.00 target price on shares of Guardant Health in a report on Monday, July 6th. The Goldman Sachs Group began coverage on shares of Guardant Health in a research report on Friday, June 5th. They issued a “buy” rating and a $165.00 price objective for the company. TD Cowen reaffirmed a “buy” rating on shares of Guardant Health in a report on Thursday, July 2nd. Wolfe Research initiated coverage on Guardant Health in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 target price on the stock. Finally, Bank of America boosted their target price on Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $160.04.

Guardant Health Stock Up 0.6%

Shares of GH opened at $155.87 on Friday. The company has a 50-day simple moving average of $134.21 and a 200-day simple moving average of $110.26. The company has a market capitalization of $20.67 billion, a PE ratio of -45.98 and a beta of 1.59. Guardant Health, Inc. has a 52-week low of $40.35 and a 52-week high of $174.08.

Guardant Health Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.